
📊 Research Summary: For early #ParkinsonDisease, nicotinamide riboside did not support disease modification, and nonmotor symptom burden worsened more than with placebo. ja.ma/3V0E912
✓JAMA is an international peer-reviewed general medical journal published weekly online and in print, and a member of the @JAMANetwork family of journals.

📊 Research Summary: For early #ParkinsonDisease, nicotinamide riboside did not support disease modification, and nonmotor symptom burden worsened more than with placebo. ja.ma/3V0E912

🧵 Among patients with early #ParkinsonDisease, treatment with nicotinamide riboside for 52 weeks did not improve clinical outcomes vs placebo and was associated with worse change in overall Movement Disorder Society Unified Parkinson Disease Rating Scale scores. These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease. ja.ma/4zTRLKL

💡 JAMA Insights: #Metabolic dysfunction-associated steatotic liver disease (#MASLD) is the most common cause of chronic #LiverDisease in children and adolescents worldwide and is often asymptomatic. This JAMA Insights indicates that screening with annual alanine aminotransferase testing starting at age 10 years is recommended for children with #obesity and for some children with #overweight or other #cardiometabolic risk factors, which may support earlier diagnosis and referral. ja.ma/4iLDqtJ

💬 Editor's Note by JAMA Associate Editor Deborah Wexler, MD, MSc, and JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS: With 1.1 billion people worldwide affected by #Obesity, newer glucagon-like peptide-1 and multiple receptor agonist therapies have changed the field, but access, adverse effects, and integration into broader strategies addressing biological, behavioral, socioeconomic, and environmental factors remain limited. This call for papers on the future of obesity seeks timely and novel research articles and opinion manuscripts on topics ranging from novel therapeutics to prevention and sustainable, comprehensive care. 🔗 Learn more: ja.ma/4zvfVdA

Join JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and leading experts in #obesity research, treatment, and policy for an inside look at Toward a Healthier Future: The #JAMASummit Report on Obesity. Featuring report authors Derek Angus, MD, MPH, Lotte Bjerre Knudsen, DMSc, Robert Kushner, MD, MS, and Marion Nestle, PhD, MPH, this discussion will examine the most important insights, debates, and priorities emerging from the Summit and explore what it will take to achieve meaningful progress in obesity prevention and treatment over the next 1-2 years. The webinar will also include a live Q&A session with the panelists. ➡️ Register now: ja.ma/4kXaG2p

Today, JAMA published Toward a Healthier Future Through Obesity Prevention and Care: The #JAMASummit Report on Obesity. The report highlights the significant opportunity presented by the emergence of effective #obesity management medications to help curb the prevalence of obesity while emphasizing that no single intervention will be sufficient to address this complex disease. 🔗 Read the full report: ja.ma/3WJvVuJ #ObesityWeek #OW2026 @ObesitySociety

💬 Editor's Note by JAMA Statistical Editor Patrick Heagerty, PhD, and Senior Statistical Editor Roger Lewis, MD, PhD: In #RandomizedClinicalTrials, treatment policy estimands address the effect of choosing one treatment over another despite treatment discontinuation or other intercurrent events, while hypothetical estimands assess outcomes under an inferred scenario in which those events did not occur. Distinguishing these approaches can improve clinical interpretation because one informs treatment choice in practice and the other reflects a best-case efficacy scenario. ja.ma/4t4VN0j #ObesityWeek #OW2026 @ObesitySociety

💬 Editorial by William Heerman, MD, MPH, Lilianna Suarez, MD, MPH, and Sarah Armstrong, MD: #PediatricObesity pharmacotherapy has shifted from limited treatment options to multiple effective choices, with tirzepatide adding substantial BMI reduction to behavioral treatment in adolescents with obesity. Clinical care now requires individualized medication selection, dose escalation, and monitoring rather than routine escalation to the maximum tolerated dose. ja.ma/4zK6jwf #ObesityWeek #OW2026 @ObesitySociety

Among adults in China with #Overweight or #Obesity without #diabetes, once-weekly ribupatide plus lifestyle intervention led to greater #WeightLoss vs placebo over 48 weeks. Ribupatide was also associated with higher likelihood of achieving prespecified weight reduction thresholds, which may inform clinical management of long-term obesity treatment. ja.ma/4iSZJwp #ObesityWeek #OW2026 @ObesitySociety

Among adolescents with #Obesity or overweight with obesity-related complications, once-weekly tirzepatide plus healthy lifestyle intervention led to greater reductions in #BMI vs placebo over 72 weeks. Tirzepatide was also associated with improvements in body weight, waist circumference, and physical functioning, supporting its potential clinical relevance for adolescent obesity treatment. ja.ma/4zQkTT7 #ObesityWeek #OW2026 @ObesitySociety

🧵 Published to coincide with #ObesityWeek 2026, these JAMA articles examine obesity treatment, clinical trial methodology, and perspectives on obesity care. Scroll through this thread to learn more.⬇️ #ObesityWeek #OW2026 @ObesitySociety

📝 JAMA Patient Page: #ChildhoodObesity is defined as a body mass index at the 95th percentile or greater for age and sex, and severe #obesity is defined as a body mass index at 120% of the 95th percentile or greater. This JAMA Patient Page explains risk factors for childhood obesity and associated conditions, including high blood pressure, abnormal #cholesterol or #triglyceride levels, fatty #LiverDisease, and increased risk of obesity, #HeartDisease, and type 2 #diabetes later in life. ja.ma/4zQZYPB

📝 #JAMAReview: #Obesity affects 15% of children aged 2 to 5 years and 22% of children aged 6 to 11 years in the US and is associated with conditions including #dyslipidemia, #hypertension, #metabolic dysfunction-associated steatotic #LiverDisease, obstructive #SleepApnea, and lower quality of life. Screening with body mass index should begin at age 2 years, and early identification and treatment may reduce risk of type 2 #diabetes, dyslipidemia, hypertension, and #mortality in adulthood. ja.ma/3WFXC7L

In 2026, the JAMA Summit on Obesity brought together an international group of cross-sector leaders to explore the issues, challenges, and opportunities to advance treatment for obesity and metabolic disorders, with a specific focus on the actionable steps that must be taken in the next 1-2 years. Building on discussions at the JAMA Summit on Obesity, this report outlines a cross-sector roadmap for improving prevention, reducing stigma, expanding equitable access to evidence-based treatment, and addressing the underlying societal and environmental drivers of the global obesity epidemic. 🔗 Read the full report: ja.ma/4t3KBkp #ObesityWeek #OW2026

The #JAMASummit Report on #Obesity identifies 3 broad targets for action: preventing obesity at the societal level, improving care for individuals living with obesity, and strengthening research and innovation. The report indicates that no single intervention is likely to be sufficient, including medication alone. Authored by more than 50 multidisciplinary experts from around the world, the report synthesizes insights from the JAMA Summit on Obesity and outlines priority actions to address one of the world’s most significant health challenges. 🔗 Read the full report: ja.ma/4t9nTrg #ObesityWeek #OW2026

What will meaningful progress in obesity prevention and care look like over the next 1-2 years? Join JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and experts from medicine, research, policy, and industry for a discussion of the JAMA Summit Report on Obesity. The webinar will explore areas of consensus and debate, emerging opportunities, persistent challenges, and priorities for action, followed by a live Q&A. ➡️ Register now: ja.ma/48uAJXs